AEON AEON Biopharma
- 0.221
- +0.011+5.24%
- 0.217
- -0.004-1.81%
AEON Biopharma News
H.C. Wainwright Maintains AEON Biopharma(AEON.US) With Buy Rating, Maintains Target Price $5
AEON Biopharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $5 Price Target
Buy Rating on AEON Biopharma: Strategic FDA Alignment and Positive Long-Term Revenue Projections
H.C. Wainwright Maintains AEON Biopharma(AEON.US) With Buy Rating, Cuts Target Price to $5
AEON Biopharma Analyst Ratings
AEON Biopharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $6 Price Target
Buy Rating Affirmed for AEON Biopharma on Strategic Biosimilar Pathway and Promising Phase 3 Study Prospects
AEON Biopharma Analyst Ratings
Buy Rating Affirmed for AEON Biopharma: Strategic Cost-Cutting and ABP-450's Broad Market Potential
HC Wainwright & Co. : The AEON Biopharma (AEON.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $18.00 to $6.00.
AEON Biopharma Analyst Ratings
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $6
Analysts Are Bullish on These Healthcare Stocks: AEON Biopharma (AEON), Palatin Technologies (PTN)
AEON Biopharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target
HC Wainwright & Co. : The AEON Biopharma (AEON.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $18.00.
AEON Biopharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target
No Data